Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
In This Article:
Satellos Bioscience (MSCL.TO) on Monday said it has completed enrollment of all four multiple-ascend
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.